Riluzole, an FDA-approved drug that inhibits the release of glutamate and is used for the treatment of amyotrophic lateral sclerosis has been shown to suppress GRM1 and the glutamate neurotransmission pathway, and decrease melanoma progression33, 34, 35. This evidence concerns the gene GRM1 and melanoma.